http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 27 Jan 2026 14:24:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Viromed+Medical+AG%3A%C2%A0MHH+to+Present+Scientific+Findings+on+Cold+Plasma+Therapy+for+Pulmonary+Application+at+Press+Conference+in+February+2026/25899648.html <p> RELLINGEN, Germany--(BUSINESS WIRE)-- On 12 February 2026, Hannover Medical School (MHH) – represented by Prof. Dr. Hortense Slevogt – plans to hold a press conference together with the team from the Helmholtz Centre for Infection Research (HZI) in Braunschweig. </p><p> The focus of the event will be the presentation and scientific classification of a groundbreaking cold plasma therapy for application in the lungs. For Viromed stakeholders, the findings are of high strategic relevance, as they address a medical field in which there is an urgent and, to date, insufficiently met clinical need worldwide: severe pulmonary infections – particularly in http://www.streetinsider.com/Press+Releases/Viromed+Medical+AG%3A%C2%A0MHH+to+Present+Scientific+Findings+on+Cold+Plasma+Therapy+for+Pulmonary+Application+at+Press+Conference+in+February+2026/25899648.html Tue, 27 Jan 2026 14:24:00 -0500 O.51121546 VMED http://www.streetinsider.com/Press+Releases/Viromed+Medical+AG%3A%C2%A0MHH+to+Present+Scientific+Findings+on+Cold+Plasma+Therapy+for+Pulmonary+Application+at+Press+Conference+in+February+2026/25899648.html <p> RELLINGEN, Germany--(BUSINESS WIRE)-- On 12 February 2026, Hannover Medical School (MHH) – represented by Prof. Dr. Hortense Slevogt – plans to hold a press conference together with the team from the Helmholtz Centre for Infection Research (HZI) in Braunschweig. </p><p> The focus of the event will be the presentation and scientific classification of a groundbreaking cold plasma therapy for application in the lungs. For Viromed stakeholders, the findings are of high strategic relevance, as they address a medical field in which there is an urgent and, to date, insufficiently met clinical need worldwide: severe pulmonary infections – particularly in http://www.streetinsider.com/Press+Releases/Viromed+Medical+AG%3A%C2%A0MHH+to+Present+Scientific+Findings+on+Cold+Plasma+Therapy+for+Pulmonary+Application+at+Press+Conference+in+February+2026/25899648.html Tue, 27 Jan 2026 14:24:00 -0500 O.51121546 VMED http://www.streetinsider.com/Business+Wire/Viromed+Medical+AG%3A%C2%A0MHH+to+Present+Scientific+Findings+on+Cold+Plasma+Therapy+for+Pulmonary+Application+at+Press+Conference+in+February+2026/25899648.html <p> RELLINGEN, Germany--(BUSINESS WIRE)-- On 12 February 2026, Hannover Medical School (MHH) – represented by Prof. Dr. Hortense Slevogt – plans to hold a press conference together with the team from the Helmholtz Centre for Infection Research (HZI) in Braunschweig. </p><p> The focus of the event will be the presentation and scientific classification of a groundbreaking cold plasma therapy for application in the lungs. For Viromed stakeholders, the findings are of high strategic relevance, as they address a medical field in which there is an urgent and, to date, insufficiently met clinical need worldwide: severe pulmonary infections – particularly in http://www.streetinsider.com/Business+Wire/Viromed+Medical+AG%3A%C2%A0MHH+to+Present+Scientific+Findings+on+Cold+Plasma+Therapy+for+Pulmonary+Application+at+Press+Conference+in+February+2026/25899648.html Tue, 27 Jan 2026 14:24:00 -0500 O.51121546 VMED http://www.streetinsider.com/Business+Wire/Viromed+Medical+AG%3A%C2%A0MHH+to+Present+Scientific+Findings+on+Cold+Plasma+Therapy+for+Pulmonary+Application+at+Press+Conference+in+February+2026/25899648.html <p> RELLINGEN, Germany--(BUSINESS WIRE)-- On 12 February 2026, Hannover Medical School (MHH) – represented by Prof. Dr. Hortense Slevogt – plans to hold a press conference together with the team from the Helmholtz Centre for Infection Research (HZI) in Braunschweig. </p><p> The focus of the event will be the presentation and scientific classification of a groundbreaking cold plasma therapy for application in the lungs. For Viromed stakeholders, the findings are of high strategic relevance, as they address a medical field in which there is an urgent and, to date, insufficiently met clinical need worldwide: severe pulmonary infections – particularly in http://www.streetinsider.com/Business+Wire/Viromed+Medical+AG%3A%C2%A0MHH+to+Present+Scientific+Findings+on+Cold+Plasma+Therapy+for+Pulmonary+Application+at+Press+Conference+in+February+2026/25899648.html Tue, 27 Jan 2026 14:24:00 -0500 O.51121546 VMED http://www.streetinsider.com/Press+Releases/Viromed+Medical+AG+reaches+milestone+for+cooperation+with+multinational+corporation/24428854.html <p> PINNEBERG, Germany--(BUSINESS WIRE)-- Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65) has reached a milestone in the extensive cooperation with a multinational corporation announced via ad hoc notification on 11 December 2024. The subject of the agreement now concluded is, in particular, the granting of a European license right in favour of Viromed Medical AG for the use of cold atmospheric pressure plasma in medicine. By granting the license rights, Viromed Medical AG is considered a manufacturer of ViroCAP® systems for use in dermatology within the meaning of the Medical Device Regulation (MDR). All intellectual property (IP) rights http://www.streetinsider.com/Press+Releases/Viromed+Medical+AG+reaches+milestone+for+cooperation+with+multinational+corporation/24428854.html Fri, 28 Feb 2025 14:02:00 -0500 A.03406950 O.00278745 VMED http://www.streetinsider.com/Press+Releases/Viromed+Medical+AG+reaches+milestone+for+cooperation+with+multinational+corporation/24428854.html <p> PINNEBERG, Germany--(BUSINESS WIRE)-- Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65) has reached a milestone in the extensive cooperation with a multinational corporation announced via ad hoc notification on 11 December 2024. The subject of the agreement now concluded is, in particular, the granting of a European license right in favour of Viromed Medical AG for the use of cold atmospheric pressure plasma in medicine. By granting the license rights, Viromed Medical AG is considered a manufacturer of ViroCAP® systems for use in dermatology within the meaning of the Medical Device Regulation (MDR). All intellectual property (IP) rights http://www.streetinsider.com/Press+Releases/Viromed+Medical+AG+reaches+milestone+for+cooperation+with+multinational+corporation/24428854.html Fri, 28 Feb 2025 14:02:00 -0500 A.03406950 O.00278745 VMED http://www.streetinsider.com/Press+Releases/Viromed+Medical+AG+reaches+milestone+for+cooperation+with+multinational+corporation/24428854.html <p> PINNEBERG, Germany--(BUSINESS WIRE)-- Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65) has reached a milestone in the extensive cooperation with a multinational corporation announced via ad hoc notification on 11 December 2024. The subject of the agreement now concluded is, in particular, the granting of a European license right in favour of Viromed Medical AG for the use of cold atmospheric pressure plasma in medicine. By granting the license rights, Viromed Medical AG is considered a manufacturer of ViroCAP® systems for use in dermatology within the meaning of the Medical Device Regulation (MDR). All intellectual property (IP) rights http://www.streetinsider.com/Press+Releases/Viromed+Medical+AG+reaches+milestone+for+cooperation+with+multinational+corporation/24428854.html Fri, 28 Feb 2025 14:02:00 -0500 A.03406950 O.00278745 VMED http://www.streetinsider.com/Business+Wire/Viromed+Medical+AG+reaches+milestone+for+cooperation+with+multinational+corporation/24428854.html <p> PINNEBERG, Germany--(BUSINESS WIRE)-- Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65) has reached a milestone in the extensive cooperation with a multinational corporation announced via ad hoc notification on 11 December 2024. The subject of the agreement now concluded is, in particular, the granting of a European license right in favour of Viromed Medical AG for the use of cold atmospheric pressure plasma in medicine. By granting the license rights, Viromed Medical AG is considered a manufacturer of ViroCAP® systems for use in dermatology within the meaning of the Medical Device Regulation (MDR). All intellectual property (IP) rights http://www.streetinsider.com/Business+Wire/Viromed+Medical+AG+reaches+milestone+for+cooperation+with+multinational+corporation/24428854.html Fri, 28 Feb 2025 14:02:00 -0500 A.03406950 O.00278745 VMED http://www.streetinsider.com/Business+Wire/Viromed+Medical+AG+reaches+milestone+for+cooperation+with+multinational+corporation/24428854.html <p> PINNEBERG, Germany--(BUSINESS WIRE)-- Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65) has reached a milestone in the extensive cooperation with a multinational corporation announced via ad hoc notification on 11 December 2024. The subject of the agreement now concluded is, in particular, the granting of a European license right in favour of Viromed Medical AG for the use of cold atmospheric pressure plasma in medicine. By granting the license rights, Viromed Medical AG is considered a manufacturer of ViroCAP® systems for use in dermatology within the meaning of the Medical Device Regulation (MDR). All intellectual property (IP) rights http://www.streetinsider.com/Business+Wire/Viromed+Medical+AG+reaches+milestone+for+cooperation+with+multinational+corporation/24428854.html Fri, 28 Feb 2025 14:02:00 -0500 A.03406950 O.00278745 VMED http://www.streetinsider.com/Business+Wire/Viromed+Medical+AG+reaches+milestone+for+cooperation+with+multinational+corporation/24428854.html <p> PINNEBERG, Germany--(BUSINESS WIRE)-- Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65) has reached a milestone in the extensive cooperation with a multinational corporation announced via ad hoc notification on 11 December 2024. The subject of the agreement now concluded is, in particular, the granting of a European license right in favour of Viromed Medical AG for the use of cold atmospheric pressure plasma in medicine. By granting the license rights, Viromed Medical AG is considered a manufacturer of ViroCAP® systems for use in dermatology within the meaning of the Medical Device Regulation (MDR). All intellectual property (IP) rights http://www.streetinsider.com/Business+Wire/Viromed+Medical+AG+reaches+milestone+for+cooperation+with+multinational+corporation/24428854.html Fri, 28 Feb 2025 14:02:00 -0500 A.03406950 O.00278745 VMED http://www.streetinsider.com/Press+Releases/Viromed+Medical+AG%3A+Cold+Plasma+as+a+Digital+Antibiotic+for+the+Lungs/24031505.html <ul class="bwlistdisc"> <li> Innovative prevention measure for ventilator-associated pneumonia reaches next stage </li> <li> Use of cold plasma can prevent tens of thousands of deaths in Germany alone </li> <li> Study led by expert from the renowned research network BREATH, Hortense Slevogt </li> </ul> <p> PINNEBERG, Germany--(BUSINESS WIRE)-- Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; “Viromed”) is pushing forward research into cold plasma for the prevention of ventilator-associated pneumonia (VAP). Under the scientific direction of the outstanding expert Prof. Dr. Hortense Slevogt, BREATH scientist at the Hannover Medical School, the innovative project is investigating the safety and efficacy of cold plasma to kill bacteria in the respiratory tract for http://www.streetinsider.com/Press+Releases/Viromed+Medical+AG%3A+Cold+Plasma+as+a+Digital+Antibiotic+for+the+Lungs/24031505.html Tue, 26 Nov 2024 03:19:00 -0500 A.11862017 VMED http://www.streetinsider.com/Press+Releases/Viromed+Medical+AG%3A+Cold+Plasma+as+a+Digital+Antibiotic+for+the+Lungs/24031505.html <ul class="bwlistdisc"> <li> Innovative prevention measure for ventilator-associated pneumonia reaches next stage </li> <li> Use of cold plasma can prevent tens of thousands of deaths in Germany alone </li> <li> Study led by expert from the renowned research network BREATH, Hortense Slevogt </li> </ul> <p> PINNEBERG, Germany--(BUSINESS WIRE)-- Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; “Viromed”) is pushing forward research into cold plasma for the prevention of ventilator-associated pneumonia (VAP). Under the scientific direction of the outstanding expert Prof. Dr. Hortense Slevogt, BREATH scientist at the Hannover Medical School, the innovative project is investigating the safety and efficacy of cold plasma to kill bacteria in the respiratory tract for http://www.streetinsider.com/Press+Releases/Viromed+Medical+AG%3A+Cold+Plasma+as+a+Digital+Antibiotic+for+the+Lungs/24031505.html Tue, 26 Nov 2024 03:19:00 -0500 A.11862017 VMED http://www.streetinsider.com/Business+Wire/Viromed+Medical+AG%3A+Cold+Plasma+as+a+Digital+Antibiotic+for+the+Lungs/24031505.html <ul class="bwlistdisc"> <li> Innovative prevention measure for ventilator-associated pneumonia reaches next stage </li> <li> Use of cold plasma can prevent tens of thousands of deaths in Germany alone </li> <li> Study led by expert from the renowned research network BREATH, Hortense Slevogt </li> </ul> <p> PINNEBERG, Germany--(BUSINESS WIRE)-- Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; “Viromed”) is pushing forward research into cold plasma for the prevention of ventilator-associated pneumonia (VAP). Under the scientific direction of the outstanding expert Prof. Dr. Hortense Slevogt, BREATH scientist at the Hannover Medical School, the innovative project is investigating the safety and efficacy of cold plasma to kill bacteria in the respiratory tract for http://www.streetinsider.com/Business+Wire/Viromed+Medical+AG%3A+Cold+Plasma+as+a+Digital+Antibiotic+for+the+Lungs/24031505.html Tue, 26 Nov 2024 03:19:00 -0500 A.11862017 VMED http://www.streetinsider.com/Business+Wire/Viromed+Medical+AG%3A+Cold+Plasma+as+a+Digital+Antibiotic+for+the+Lungs/24031505.html <ul class="bwlistdisc"> <li> Innovative prevention measure for ventilator-associated pneumonia reaches next stage </li> <li> Use of cold plasma can prevent tens of thousands of deaths in Germany alone </li> <li> Study led by expert from the renowned research network BREATH, Hortense Slevogt </li> </ul> <p> PINNEBERG, Germany--(BUSINESS WIRE)-- Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; “Viromed”) is pushing forward research into cold plasma for the prevention of ventilator-associated pneumonia (VAP). Under the scientific direction of the outstanding expert Prof. Dr. Hortense Slevogt, BREATH scientist at the Hannover Medical School, the innovative project is investigating the safety and efficacy of cold plasma to kill bacteria in the respiratory tract for http://www.streetinsider.com/Business+Wire/Viromed+Medical+AG%3A+Cold+Plasma+as+a+Digital+Antibiotic+for+the+Lungs/24031505.html Tue, 26 Nov 2024 03:19:00 -0500 A.11862017 VMED http://www.streetinsider.com/Press+Releases/Viromed+Medical+AG+Plans+to+Acquire+All+Shares+of+ActivCell+Group+AG+by+Way+of+a+Capital+Increase+Against+Contribution+in+Kind+with+Exclusion+of+Subscription+Rights/23731833.html <p> PINNEBERG, Germany--(BUSINESS WIRE)-- Viromed Medical AG (Ticker: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Feqs-cockpit.com%2Fcgi-bin%2Ffncls.ssp%3Ffn%3Dredirect%26url%3D03003d462bf07ae5fbd5a9dd7d755919%26application_id%3D1989895%26site_id%3Dnews_data%26application_name%3Dnews&amp;esheet=54123366&amp;newsitemid=20240917445870&amp;lan=en-US&amp;anchor=VMED&amp;index=1&amp;md5=7535a17837df69d48b29883fc59cf5bf" shape="rect">VMED</a>; ISIN: DE000A3MQR65; “Viromed”; the “Company”) plans to acquire all shares in ActivCell Group AG, Switzerland, and thus strategically expand its product portfolio. To this end, the Company has today signed a term sheet with the owners of ActivCell Group AG and will immediately enter into further negotiations with the objective of concluding an agreement. With the acquisition of ActivCell Group AG, Viromed expands the treatment spectrum of its products with additional indications and expects an accelerated market launch in the European Union with its own http://www.streetinsider.com/Press+Releases/Viromed+Medical+AG+Plans+to+Acquire+All+Shares+of+ActivCell+Group+AG+by+Way+of+a+Capital+Increase+Against+Contribution+in+Kind+with+Exclusion+of+Subscription+Rights/23731833.html Tue, 17 Sep 2024 12:30:00 -0500 A.50200526 O.19887974 VMED http://www.streetinsider.com/Press+Releases/Viromed+Medical+AG+Plans+to+Acquire+All+Shares+of+ActivCell+Group+AG+by+Way+of+a+Capital+Increase+Against+Contribution+in+Kind+with+Exclusion+of+Subscription+Rights/23731833.html <p> PINNEBERG, Germany--(BUSINESS WIRE)-- Viromed Medical AG (Ticker: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Feqs-cockpit.com%2Fcgi-bin%2Ffncls.ssp%3Ffn%3Dredirect%26url%3D03003d462bf07ae5fbd5a9dd7d755919%26application_id%3D1989895%26site_id%3Dnews_data%26application_name%3Dnews&amp;esheet=54123366&amp;newsitemid=20240917445870&amp;lan=en-US&amp;anchor=VMED&amp;index=1&amp;md5=7535a17837df69d48b29883fc59cf5bf" shape="rect">VMED</a>; ISIN: DE000A3MQR65; “Viromed”; the “Company”) plans to acquire all shares in ActivCell Group AG, Switzerland, and thus strategically expand its product portfolio. To this end, the Company has today signed a term sheet with the owners of ActivCell Group AG and will immediately enter into further negotiations with the objective of concluding an agreement. With the acquisition of ActivCell Group AG, Viromed expands the treatment spectrum of its products with additional indications and expects an accelerated market launch in the European Union with its own http://www.streetinsider.com/Press+Releases/Viromed+Medical+AG+Plans+to+Acquire+All+Shares+of+ActivCell+Group+AG+by+Way+of+a+Capital+Increase+Against+Contribution+in+Kind+with+Exclusion+of+Subscription+Rights/23731833.html Tue, 17 Sep 2024 12:30:00 -0500 A.50200526 O.19887974 VMED http://www.streetinsider.com/Press+Releases/Viromed+Medical+AG+Plans+to+Acquire+All+Shares+of+ActivCell+Group+AG+by+Way+of+a+Capital+Increase+Against+Contribution+in+Kind+with+Exclusion+of+Subscription+Rights/23731833.html <p> PINNEBERG, Germany--(BUSINESS WIRE)-- Viromed Medical AG (Ticker: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Feqs-cockpit.com%2Fcgi-bin%2Ffncls.ssp%3Ffn%3Dredirect%26url%3D03003d462bf07ae5fbd5a9dd7d755919%26application_id%3D1989895%26site_id%3Dnews_data%26application_name%3Dnews&amp;esheet=54123366&amp;newsitemid=20240917445870&amp;lan=en-US&amp;anchor=VMED&amp;index=1&amp;md5=7535a17837df69d48b29883fc59cf5bf" shape="rect">VMED</a>; ISIN: DE000A3MQR65; “Viromed”; the “Company”) plans to acquire all shares in ActivCell Group AG, Switzerland, and thus strategically expand its product portfolio. To this end, the Company has today signed a term sheet with the owners of ActivCell Group AG and will immediately enter into further negotiations with the objective of concluding an agreement. With the acquisition of ActivCell Group AG, Viromed expands the treatment spectrum of its products with additional indications and expects an accelerated market launch in the European Union with its own http://www.streetinsider.com/Press+Releases/Viromed+Medical+AG+Plans+to+Acquire+All+Shares+of+ActivCell+Group+AG+by+Way+of+a+Capital+Increase+Against+Contribution+in+Kind+with+Exclusion+of+Subscription+Rights/23731833.html Tue, 17 Sep 2024 12:30:00 -0500 A.50200526 O.19887974 VMED http://www.streetinsider.com/Business+Wire/Viromed+Medical+AG+Plans+to+Acquire+All+Shares+of+ActivCell+Group+AG+by+Way+of+a+Capital+Increase+Against+Contribution+in+Kind+with+Exclusion+of+Subscription+Rights/23731833.html <p> PINNEBERG, Germany--(BUSINESS WIRE)-- Viromed Medical AG (Ticker: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Feqs-cockpit.com%2Fcgi-bin%2Ffncls.ssp%3Ffn%3Dredirect%26url%3D03003d462bf07ae5fbd5a9dd7d755919%26application_id%3D1989895%26site_id%3Dnews_data%26application_name%3Dnews&amp;esheet=54123366&amp;newsitemid=20240917445870&amp;lan=en-US&amp;anchor=VMED&amp;index=1&amp;md5=7535a17837df69d48b29883fc59cf5bf" shape="rect">VMED</a>; ISIN: DE000A3MQR65; “Viromed”; the “Company”) plans to acquire all shares in ActivCell Group AG, Switzerland, and thus strategically expand its product portfolio. To this end, the Company has today signed a term sheet with the owners of ActivCell Group AG and will immediately enter into further negotiations with the objective of concluding an agreement. With the acquisition of ActivCell Group AG, Viromed expands the treatment spectrum of its products with additional indications and expects an accelerated market launch in the European Union with its own http://www.streetinsider.com/Business+Wire/Viromed+Medical+AG+Plans+to+Acquire+All+Shares+of+ActivCell+Group+AG+by+Way+of+a+Capital+Increase+Against+Contribution+in+Kind+with+Exclusion+of+Subscription+Rights/23731833.html Tue, 17 Sep 2024 12:30:00 -0500 A.50200526 O.19887974 VMED http://www.streetinsider.com/Business+Wire/Viromed+Medical+AG+Plans+to+Acquire+All+Shares+of+ActivCell+Group+AG+by+Way+of+a+Capital+Increase+Against+Contribution+in+Kind+with+Exclusion+of+Subscription+Rights/23731833.html <p> PINNEBERG, Germany--(BUSINESS WIRE)-- Viromed Medical AG (Ticker: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Feqs-cockpit.com%2Fcgi-bin%2Ffncls.ssp%3Ffn%3Dredirect%26url%3D03003d462bf07ae5fbd5a9dd7d755919%26application_id%3D1989895%26site_id%3Dnews_data%26application_name%3Dnews&amp;esheet=54123366&amp;newsitemid=20240917445870&amp;lan=en-US&amp;anchor=VMED&amp;index=1&amp;md5=7535a17837df69d48b29883fc59cf5bf" shape="rect">VMED</a>; ISIN: DE000A3MQR65; “Viromed”; the “Company”) plans to acquire all shares in ActivCell Group AG, Switzerland, and thus strategically expand its product portfolio. To this end, the Company has today signed a term sheet with the owners of ActivCell Group AG and will immediately enter into further negotiations with the objective of concluding an agreement. With the acquisition of ActivCell Group AG, Viromed expands the treatment spectrum of its products with additional indications and expects an accelerated market launch in the European Union with its own http://www.streetinsider.com/Business+Wire/Viromed+Medical+AG+Plans+to+Acquire+All+Shares+of+ActivCell+Group+AG+by+Way+of+a+Capital+Increase+Against+Contribution+in+Kind+with+Exclusion+of+Subscription+Rights/23731833.html Tue, 17 Sep 2024 12:30:00 -0500 A.50200526 O.19887974 VMED http://www.streetinsider.com/Business+Wire/Viromed+Medical+AG+Plans+to+Acquire+All+Shares+of+ActivCell+Group+AG+by+Way+of+a+Capital+Increase+Against+Contribution+in+Kind+with+Exclusion+of+Subscription+Rights/23731833.html <p> PINNEBERG, Germany--(BUSINESS WIRE)-- Viromed Medical AG (Ticker: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Feqs-cockpit.com%2Fcgi-bin%2Ffncls.ssp%3Ffn%3Dredirect%26url%3D03003d462bf07ae5fbd5a9dd7d755919%26application_id%3D1989895%26site_id%3Dnews_data%26application_name%3Dnews&amp;esheet=54123366&amp;newsitemid=20240917445870&amp;lan=en-US&amp;anchor=VMED&amp;index=1&amp;md5=7535a17837df69d48b29883fc59cf5bf" shape="rect">VMED</a>; ISIN: DE000A3MQR65; “Viromed”; the “Company”) plans to acquire all shares in ActivCell Group AG, Switzerland, and thus strategically expand its product portfolio. To this end, the Company has today signed a term sheet with the owners of ActivCell Group AG and will immediately enter into further negotiations with the objective of concluding an agreement. With the acquisition of ActivCell Group AG, Viromed expands the treatment spectrum of its products with additional indications and expects an accelerated market launch in the European Union with its own http://www.streetinsider.com/Business+Wire/Viromed+Medical+AG+Plans+to+Acquire+All+Shares+of+ActivCell+Group+AG+by+Way+of+a+Capital+Increase+Against+Contribution+in+Kind+with+Exclusion+of+Subscription+Rights/23731833.html Tue, 17 Sep 2024 12:30:00 -0500 A.50200526 O.19887974 VMED http://www.streetinsider.com/13Fs/Loeb%27s+Third+Point+Enters+Walt+Disney+%28DIS%29%3B+Boosts+Sothebys+%28BID%29%2C+Sells+SPDR+Gold+%28GLD%29/8604830.html si-local-file:///var/storage/newsbody/2013/0814/8604830.html http://www.streetinsider.com/13Fs/Loeb%27s+Third+Point+Enters+Walt+Disney+%28DIS%29%3B+Boosts+Sothebys+%28BID%29%2C+Sells+SPDR+Gold+%28GLD%29/8604830.html Wed, 14 Aug 2013 18:06:56 -0500 AAPL ABBV AGU AIG APC ARIA BEAV BID BIOF CBD CCE CIM COG DG DIS DLPH EA EEM ELN ENPH EQIX GILD GLD HES HSH IP LBTYA LBTYK LNG LPX LYB MPC MUR NWSA NXPI PSS ST TDG TIBX TIF TMO VMED WCC WMB YHOO http://www.streetinsider.com/13Fs/Loeb%27s+Third+Point+Enters+Walt+Disney+%28DIS%29%3B+Boosts+Sothebys+%28BID%29%2C+Sells+SPDR+Gold+%28GLD%29/8604830.html si-local-file:///var/storage/newsbody/2013/0814/8604830.html http://www.streetinsider.com/13Fs/Loeb%27s+Third+Point+Enters+Walt+Disney+%28DIS%29%3B+Boosts+Sothebys+%28BID%29%2C+Sells+SPDR+Gold+%28GLD%29/8604830.html Wed, 14 Aug 2013 18:06:56 -0500 AAPL ABBV AGU AIG APC ARIA BEAV BID BIOF CBD CCE CIM COG DG DIS DLPH EA EEM ELN ENPH EQIX GILD GLD HES HSH IP LBTYA LBTYK LNG LPX LYB MPC MUR NWSA NXPI PSS ST TDG TIBX TIF TMO VMED WCC WMB YHOO http://www.streetinsider.com/13Fs/Loeb%27s+Third+Point+Enters+Walt+Disney+%28DIS%29%3B+Boosts+Sothebys+%28BID%29%2C+Sells+SPDR+Gold+%28GLD%29/8604830.html si-local-file:///var/storage/newsbody/2013/0814/8604830.html http://www.streetinsider.com/13Fs/Loeb%27s+Third+Point+Enters+Walt+Disney+%28DIS%29%3B+Boosts+Sothebys+%28BID%29%2C+Sells+SPDR+Gold+%28GLD%29/8604830.html Wed, 14 Aug 2013 18:06:56 -0500 AAPL ABBV AGU AIG APC ARIA BEAV BID BIOF CBD CCE CIM COG DG DIS DLPH EA EEM ELN ENPH EQIX GILD GLD HES HSH IP LBTYA LBTYK LNG LPX LYB MPC MUR NWSA NXPI PSS ST TDG TIBX TIF TMO VMED WCC WMB YHOO http://www.streetinsider.com/13Fs/Loeb%27s+Third+Point+Enters+Walt+Disney+%28DIS%29%3B+Boosts+Sothebys+%28BID%29%2C+Sells+SPDR+Gold+%28GLD%29/8604830.html si-local-file:///var/storage/newsbody/2013/0814/8604830.html http://www.streetinsider.com/13Fs/Loeb%27s+Third+Point+Enters+Walt+Disney+%28DIS%29%3B+Boosts+Sothebys+%28BID%29%2C+Sells+SPDR+Gold+%28GLD%29/8604830.html Wed, 14 Aug 2013 18:06:56 -0500 AAPL ABBV AGU AIG APC ARIA BEAV BID BIOF CBD CCE CIM COG DG DIS DLPH EA EEM ELN ENPH EQIX GILD GLD HES HSH IP LBTYA LBTYK LNG LPX LYB MPC MUR NWSA NXPI PSS ST TDG TIBX TIF TMO VMED WCC WMB YHOO http://www.streetinsider.com/13Fs/Loeb%27s+Third+Point+Enters+Walt+Disney+%28DIS%29%3B+Boosts+Sothebys+%28BID%29%2C+Sells+SPDR+Gold+%28GLD%29/8604830.html si-local-file:///var/storage/newsbody/2013/0814/8604830.html http://www.streetinsider.com/13Fs/Loeb%27s+Third+Point+Enters+Walt+Disney+%28DIS%29%3B+Boosts+Sothebys+%28BID%29%2C+Sells+SPDR+Gold+%28GLD%29/8604830.html Wed, 14 Aug 2013 18:06:56 -0500 AAPL ABBV AGU AIG APC ARIA BEAV BID BIOF CBD CCE CIM COG DG DIS DLPH EA EEM ELN ENPH EQIX GILD GLD HES HSH IP LBTYA LBTYK LNG LPX LYB MPC MUR NWSA NXPI PSS ST TDG TIBX TIF TMO VMED WCC WMB YHOO